A recently published meta-analysis of randomized trials concludes CoQ10 has some efficacy in the treatment of depresssion at doses of 100-500mg.
Depression is a well-known risk factor for CVD.
William Wallace shares a meta-analysis of randomized trials finding CoQ10, mostly as add-on therapy, improved depressive symptoms with a moderate effect size. He notes depression is a CVD risk factor. Dose and form conclusions are limited.
A recently published meta-analysis of randomized trials concludes CoQ10 has some efficacy in the treatment of depresssion at doses of 100-500mg.
Depression is a well-known risk factor for CVD.
RCTs report improvements in depressive symptoms using 100–500 mg/day, studied primarily as an adjunctive strategy. The pooled data showed a moderate effect size and consistent results across validated scales
Depression is increasingly linked to mitochondrial dysfunction and inflammation, both of which implicate impaired energy availability. CoQ10 plays a central role in ATP production, acts as a lipid-soluble antioxidant, and may help modulate inflammatory signaling, making it biologically plausible as a supportive intervention for treating depression.
No single “right” dose; no form-specific conclusions; and, of course, context matters.
In all, another potential "tool" to support those in need.
PMID: 41294251